According to Medscape, a recent study explored the efficacy of armodafinil to treat insomnia in cancer patients.
“The failure of armodafinil to produce benefits additive to those of CBT-I for the treatment of insomnia should discourage the use of this drug in oncologic practice,” Dr Roscoe and colleagues conclude.
